New drug combo shows promise for kids with resistant cancers
NCT ID NCT01282697
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 33 times
Summary
This early-stage trial tested a combination of two drugs, rapamycin and irinotecan, in 42 children and young adults aged 1 to 21 with solid tumors that had stopped responding to standard treatments. The main goal was to find the safest dose and understand side effects. The drugs work by blocking blood vessel growth in tumors, which may stop or slow tumor progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY SOLID TUMORS IN CHILDREN are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CHU La Timone
Marseille, 13005, France
-
CHU Mère-Enfants
Nantes, 44093, France
-
Centre Oscar Lambret
Lille, 59020, France
-
Hôpital des Enfants
Toulouse, 31059, France
-
Hôpital des Enfants - Groupe Hospitalier Pellegrin
Bordeaux, 33076, France
-
Hôpitaux Universitaires de Strasbourg
Strasbourg, 67098, France
-
Institut Curie
Paris, 75005, France
-
Institut Gustave Roussy
Villejuif, 94805, France
-
Institut Hémato-Oncologie Pédiatrique (IHOP)
Lyon, 67008, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
rapamycin and irinotecan
What this could lead to
If this combination proves safe and effective, it could offer a new treatment option for children with solid tumors that no longer respond to standard therapies.
What could go wrong
This is an early phase I trial with only 42 participants, focused on safety and dosing, not on proving the treatment works. The combination may cause significant side effects or fail to shrink tumors.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.